Gail E Atkinson

Title: Gail E Atkinson: Innovator in p21 Peptides

Introduction

Gail E Atkinson is a notable inventor based in Beverley, GB. She has made significant contributions to the field of biochemistry, particularly through her work on p21 derived peptides. Her innovative approach has led to advancements in the inhibition of CDK/cyclin complexes, which are crucial in cell cycle regulation.

Latest Patents

Gail E Atkinson holds 1 patent related to her research on p21 peptides. The patent describes peptides derived from the C-terminal region of p21 that are capable of inhibiting CDK/cyclin complexes, specifically targeting cyclins A or E/CDK2. These peptides exhibit selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Notably, variants of these peptides, particularly those involving certain alanine replacements, have been shown to be particularly potent.

Career Highlights

Gail E Atkinson is associated with Cyclacel Limited, where she continues to explore the potential of her discoveries in the pharmaceutical industry. Her work has implications for cancer treatment, as the regulation of the cell cycle is a critical factor in tumor growth and development.

Collaborations

Gail has collaborated with esteemed colleagues such as Daniella I Zheleva and Peter Martin Fischer, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Gail E Atkinson's contributions to the field of biochemistry, particularly through her work on p21 peptides, highlight her role as an influential inventor. Her research not only advances scientific understanding but also holds promise for future therapeutic applications.